Reilly Financial Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Reilly Financial Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-425	Closed	-$11K	–	890
2019 Q2	$11K	Hold	425	–	–	﹤0.01%	643
2019 Q1	$11K	Hold	425	–	–	﹤0.01%	651
2018 Q4	$7K	Hold	425	–	–	﹤0.01%	696
2018 Q3	$9K	Hold	425	–	–	﹤0.01%	717
2018 Q2	$6K	Sell	425 -2,000	-82%	-$35.7K	﹤0.01%	766
2018 Q1	$54K	Buy	2,425 +1,000	+70%	+$27.7K	0.01%	291
2017 Q4	$43K	Buy	1,425 +1,000	+235%	+$32K	0.01%	347
2017 Q3	$16K	Hold	425	–	–	﹤0.01%	542
2017 Q2	$12K	Hold	425	–	–	﹤0.01%	601
2017 Q1	$15K	Hold	425	–	–	﹤0.01%	528
2016 Q4	$12K	Hold	425	–	–	﹤0.01%	521
2016 Q3	$14K	Hold	425	–	–	﹤0.01%	457
2016 Q2	$14K	Hold	425	–	–	﹤0.01%	433
2016 Q1	$12K	Buy	+425	New	+$9.27K	﹤0.01%	709
2015 Q1	–	Sell	-100	Closed	-$3K	–	1285
2014 Q4	$3K	Hold	100	–	–	﹤0.01%	691
2014 Q3	$2K	Buy	+100	New	+$2.34K	﹤0.01%	758

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Reilly Financial Advisors's ACAD Position: Q3 2019 in Review

Reilly Financial Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q3 2019, closing a stake of 425 shares — an estimated $11K sold.

Reilly Financial Advisors first reported a position in ACAD in Q3 2014 and held it in 16 quarters. The position peaked at $54K in Q1 2018. 231 funds tracked by Wall St. Rank hold ACAD as of Q3 2019.

Reilly Financial Advisors reported no remaining Acadia Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Reilly Financial Advisors sold 425 Acadia Pharmaceuticals shares in Q3 2019, an estimated $11K.
Reilly Financial Advisors first reported a position in Acadia Pharmaceuticals in Q3 2014 and held it in 16 quarters.
Reilly Financial Advisors's Acadia Pharmaceuticals position peaked at $54K in Q1 2018.
231 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2019.

Based on Reilly Financial Advisors's 13F filing for Q3 2019, filed 15 Oct 2019.